Table 2.
Clinically tested drugs that affect pulmonary vasoconstriction that could be used in COVID-19.
| Drug Name | Target | Other Beneficial Effects | References |
|---|---|---|---|
| 4-methylumbelliferone (4MU) | Hyaluronan inhibitor | [129,130] | |
| Captopril | ACE inhibitors | [75,76] | |
| Icatibant | Selective antagonist for the B2 receptor | Reduction of cough symptoms and edema | [63,64] |
| Ifetroban | Thromboxane A2 antagonist | Inhibition of thrombotic processes | [155] |
| Lanadelumab | A monoclonal antibody (class IgG1 kappa) against high-molecular-weight kininogen that yields bradykinin | Reduction of cough symptoms and edema | [59,67] |
| Losartan | An angiotensin II receptor blocker (ARB) | Reduction of inflammation | [77] |
| Macitentan (ACT-064992), Bosentan | Prevents the binding of ET-1 to both endothelin A (ETA) and endothelin B (ETB) receptors (endothelin receptor antagonist) | Inhibition of inflammation, Reduction of viral RNA counts | [135] |